Acetylcholine receptor antibody-positive myasthenia gravis (AChR-MG) is a rare autoimmune disease in which AChR autoantibodies trigger complement activation and cause damage to the neuromuscular junction. This study evaluated the therapeutic potential of an anti-C2 antibody in the rat passive transfer model of myasthenia gravis (PTMG). Female Lewis rats (n = 36) were prophylactically treated with either an anti-rat C2 antibody or an IgG isotype control two hours prior to subcutaneous injection of mAb35 (PTMG) or saline (non-MG). Serum samples were collected at several timepoints during the study and muscle weakness; body weight and clinical manifestations were assessed daily. The animals underwent electromyography prior to euthanasia. AChR content in the tibialis anterior was determined by radioimmunoassay. Anti-C2 antibody-treated animals maintained body weight, grip strength and muscle AChR content (both functional and total) at levels comparable to non-MG animals. Serum analyses confirmed reduced complement activity over the course of the experiment in anti-C2 treated animals. These findings indicate that anti-C2 treatment effectively prevents disease development in this model, supporting its potential as a therapeutic strategy for managing AChR-MG.
Britt Arets, Siyang Peng, Pilar Martinez-Martinez, See PDF. Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis. // Journal of Translational Autoimmunity. – DOI: 10.2139/ssrn.6925166. – URL: https://www.sciencedirect.com/science/article/pii/S2589909026000419?dgcid=rss_sd_all
Britt Arets, Siyang Peng, Pilar Martinez-Martinez, & See PDF Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis. Journal of Translational Autoimmunity. https://doi.org/10.2139/ssrn.6925166
Britt Arets, et al. “Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis.” Journal of Translational Autoimmunity. doi:10.2139/ssrn.6925166.
@article{Arets,
title = {Anti-C2–mediated complement inhibition prevents disease in a rat passive transfer model of myasthenia gravis},
author = {Arets, Britt and Peng, Siyang and Martinez-Martinez, Pilar and PDF, See},
journal = {Journal of Translational Autoimmunity},
doi = {10.2139/ssrn.6925166},
url = {https://www.sciencedirect.com/science/article/pii/S2589909026000419?dgcid=rss_sd_all}
}
Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents in regenerative medicine, with their therapeutic effects increasingly attributed to intercellular communication and microenvironmental regulation rather than...
Background Scleral remodeling with myofibroblast activation and extracellular matrix (ECM) degradation drives myopia, but mechanisms remain unclear. This study explored USP33’s role and its regulatory network. Methods We analyzed GEO...
Background Lung cancer is one of the leading causes of cancer-related mortality worldwide. Understanding the molecular mechanisms underlying lung cancer progression is critical for identifying novel therapeutic targets. This study...